Assessment of the metabolism of therapeutic proteins and antibodies

Bibliography

• FDA. Guidance for Industry: S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. Food and Drug Administration. 1997. Available from: http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm129171.pdf
   Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22:868-76
   PubMed Web of Science ®Google Scholar
• EMEA. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. European Medecines Agency. 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029.pdf
   Google Scholar
• Katsila T, Siskos AP, Tamvakopoulos C. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev 2012;31:110-33
   PubMed Web of Science ®Google Scholar
• Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J 2012;14:781-91
   PubMed Web of Science ®Google Scholar
• Hamuro LL, Kishnani NS. Metabolism of biologics: biotherapeutic proteins. Bioanalysis 2012;4:189-95
   PubMed Web of Science ®Google Scholar
• Lee JW. ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis 2013;5:2003-14
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
   PubMed Web of Science ®Google Scholar
• Ezan E. Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 2013;65:1065-73
   PubMed Web of Science ®Google Scholar
• Wang W, Chen N, Shen X, et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 2012;40:952-62
   PubMed Web of Science ®Google Scholar
• Zou Y, Bateman TJ, Adreani C, et al. Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats. Drug Metab Dispos 2013;41:2206-14
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011;117:4787-95
   PubMed Web of Science ®Google Scholar
• Golor G, sen-Kennedy D, Haffner S, et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J Thromb Haemost 2013;11:1977-85
   PubMed Web of Science ®Google Scholar
• Uhl W, Zuhlsdorf M, Koernicke T, et al. Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 2014;32(2):347-54
   PubMed Web of Science ®Google Scholar
• Segrave AM, Mager DE, Charman SA, et al. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther 2004;309:1085-92
   PubMed Web of Science ®Google Scholar
• Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820-4
   PubMed Web of Science ®Google Scholar
• Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008;14:191-202
   PubMedGoogle Scholar
• Vugmeyster Y, Xu X, Theil FP, et al. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 2012;3:73-92
   PubMedGoogle Scholar
• Kato M, Miura K, Kamiyama H, et al. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. Drug Metab Dispos 1997;25:1039-44
   PubMed Web of Science ®Google Scholar
• Fischer KG, Liebe V, Hudek R, et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003;89:973-82
   PubMed Web of Science ®Google Scholar
• Tagliaro F, Dorizzi R, Luisetto G. Effect of antibodies to calcitonin on the pharmacokinetics and the pharmacodynamics of the hormone. Horm Metab Res 1995;27:31-4
   PubMed Web of Science ®Google Scholar
• Christensen EI. Rapid protein uptake and digestion in proximal tubule lysosomes. Kidney Int 1976;10:301-10
   PubMed Web of Science ®Google Scholar
• Saito A, Sato H, Iino N, Takeda T. Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium. J Biomed Biotechnol 2010;2010:403272
   PubMed Web of Science ®Google Scholar
• Postel-Vinay MC, Kayser C, Desbuquois B. Fate of injected human growth hormone in the female rat liver in vivo. Endocrinology 1982;111:244-51
   PubMed Web of Science ®Google Scholar
• Opanasopit P, Nishikawa M, Yamashita F, et al. Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells. J Drug Target 2001;9:341-51
   PubMed Web of Science ®Google Scholar
• Higuchi Y, Nishikawa M, Kawakami S, et al. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 2004;287:147-54
   PubMed Web of Science ®Google Scholar
• Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Rath T, Kuo TT, Baker K, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013;33(Suppl 1):S9-17
   Google Scholar
• Chen X, Zaro JL, Shen WC. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 2012;8:581-95
   PubMed Web of Science ®Google Scholar
• Hager T, Spahr C, Xu J, et al. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem 2013;85:2731-8
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012;161:461-72
   PubMed Web of Science ®Google Scholar
• Nadeau RW, Satoh H, Scheide S, et al. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys. Drug Metab Dispos 1995;23:904-9
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Cao K, et al. Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic. Drug Metab Dispos 2012;40:1677-85
   PubMed Web of Science ®Google Scholar
• Xiang H, Nguyen CB, Kelley SK, et al. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004;32:1230-8
   PubMed Web of Science ®Google Scholar
• Ferraiolo BL, Moore JA, Crase D, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab Dispos 1988;16:270-5
   PubMed Web of Science ®Google Scholar
• Mesmin C, Renvoise M, Becher F, et al. MS-based approaches to unravel the molecular complexity of proprotein-derived biomarkers and support their quantification: the examples of B-type natriuretic peptide and apelin peptides. Bioanalysis 2012;4:2851-63
   PubMed Web of Science ®Google Scholar
• Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 1999;27:21-5
   PubMed Web of Science ®Google Scholar
• Chen SA, Sawchuk RJ, Brundage RC, et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 2000;293:248-59
   Google Scholar
• Pascual MH, Verdier P, Malette P, et al. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate – SAR566658 – for pharmacokinetic interpretation improvement. J Immunol Methods 2013;396:140-6
   PubMed Web of Science ®Google Scholar
• Stephan JP, Chan P, Lee C, et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 2008;19:1673-83
   PubMed Web of Science ®Google Scholar
• Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev 2007;26:370-88
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Ayoub D, et al. Characterization of therapeutic antibodies and related products. Anal Chem 2013;85:715-36
   PubMed Web of Science ®Google Scholar
• Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006;312:212-17
   PubMed Web of Science ®Google Scholar
• Macht M. Mass spectrometric top-down analysis of proteins. Bioanalysis 2009;1:1131-48
   PubMed Web of Science ®Google Scholar
• Macht M. Top-down characterization of biopharmaceuticals. Trends Anal Chem 2013;48:62-71
   Web of Science ®Google Scholar
• Savaryn JP, Catherman AD, Thomas PM, et al. The emergence of top-down proteomics in clinical research. Genome Med 2013;5:53
   PubMedGoogle Scholar
• van Dongen WD, Niessen WM. LC-MS systems for quantitative bioanalysis. Bioanalysis 2012;4:2391-9
   PubMed Web of Science ®Google Scholar
• van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci 2013;929:161-79
   PubMed Web of Science ®Google Scholar
• Hagman C, Ricke D, Ewert S, et al. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal Chem 2008;80:1290-6
   PubMed Web of Science ®Google Scholar
• Heudi O, Barteau S, Zimmer D, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008;80:4200-7
   PubMed Web of Science ®Google Scholar
• Yang Z, Hayes M, Fang X, et al. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal Chem 2007;79:9294-301
   PubMed Web of Science ®Google Scholar
• Dubois M, Fenaille F, Clement G, et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008;80:1737-45
   PubMed Web of Science ®Google Scholar
• Becher F, Pruvost A, Clement G, et al. Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. Anal Chem 2006;78:2306-13
   PubMed Web of Science ®Google Scholar
• Ji QC, Rodila R, Gage EM, El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal Chem 2003;75:7008-14
   PubMed Web of Science ®Google Scholar
• Li H, Ortiz R, Tran L, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 2012;84:1267-73
   PubMed Web of Science ®Google Scholar
• Mesmin C, Fenaille F, Ezan E, Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 2011;3:477-80
   PubMed Web of Science ®Google Scholar
• Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009;134:825-34
   PubMed Web of Science ®Google Scholar
• Dubois M, Becher F, Herbet A, Ezan E. Immuno-mass spectrometry assay of EPI-HNE4, a recombinant protein inhibitor of human elastase. Rapid Commun Mass Spectrom 2007;21:352-8
   PubMed Web of Science ®Google Scholar
• Shi T, Fillmore TL, Sun X, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci USA 2012;109:15395-400
   PubMed Web of Science ®Google Scholar
• Fernandez OM, James IT, Kabir M, et al. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS. Anal Chem 2012;84:5959-67
   PubMed Web of Science ®Google Scholar
• Xu Y, Mehl JT, Bakhtiar R, Woolf EJ. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal Chem 2010;82:6877-86
   PubMed Web of Science ®Google Scholar
• Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11
   PubMed Web of Science ®Google Scholar
• Zhang CX, Weber BV, Thammavong J, et al. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 2006;78:1636-43
   PubMed Web of Science ®Google Scholar
• Thevis M, Thomas A, Schanzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 2008;27:35-50
   PubMed Web of Science ®Google Scholar
• Hall MP, Gegg C, Walker K, et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 2010;12:576-85
   PubMed Web of Science ®Google Scholar
• Hecht R, Li YS, Sun J, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes. PLoS One 2012;7:e49345
   PubMed Web of Science ®Google Scholar
• Wroblewski VJ, Witcher DR, Becker GW, et al. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol 2003;65:657-67
   PubMed Web of Science ®Google Scholar
• Wroblewski VJ, McCloud C, Davis K, et al. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos 2003;31:502-7
   PubMed Web of Science ®Google Scholar
• Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov Today 2010;15:773-80
   PubMed Web of Science ®Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4:419-25
   PubMed Web of Science ®Google Scholar
• Stahl PD. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992;4:49-52
   PubMed Web of Science ®Google Scholar
• Jones AJ, Papac DI, Chin EH, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007;17:529-40
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009;19:240-9
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011;21:949-59
   PubMed Web of Science ®Google Scholar
• Hong Q, Lebrilla CB, Miyamoto S, Ruhaak LR. Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem 2013;85:8585-93
   PubMed Web of Science ®Google Scholar
• Xu K, Liu L, Saad OM, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 2011;412:56-66
   PubMed Web of Science ®Google Scholar
• Kaur S, Xu K, Saad OM, et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013;5:201-26
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011;3:161-72
   PubMed Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
   PubMed Web of Science ®Google Scholar
• Chen J, Yin S, Wu Y, Ouyang J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal Chem 2013;85:1699-704
   PubMed Web of Science ®Google Scholar
• Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 2012;11:1475-88
   PubMed Web of Science ®Google Scholar
• Gallien S, Duriez E, Crone C, et al. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics 2012;11:1709-23
   PubMed Web of Science ®Google Scholar
• Shliaha PV, Bond NJ, Gatto L, Lilley KS. Effects of traveling wave ion mobility separation on data independent acquisition in proteomics studies. J Proteome Res 2013;12:2323-39
   PubMed Web of Science ®Google Scholar
• Cindric M, Cepo T, Galic N, et al. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharm Biomed Anal 2007;44:388-95
   PubMed Web of Science ®Google Scholar
• Seyfried BK, Siekmann J, Belgacem O, et al. MALDI linear TOF mass spectrometry of PEGylated (glyco)proteins. J Mass Spectrom 2010;45:612-17
   PubMed Web of Science ®Google Scholar
• Yoo C, Suckau D, Sauerland V, et al. Toward top-down determination of PEGylation site using MALDI in-source decay MS analysis. J Am Soc Mass Spectrom 2009;20:326-33
   PubMed Web of Science ®Google Scholar
• Forstenlehner IC, Holzmann J, Scheffler K, et al. A direct-infusion- and HPLC-ESI-orbitrap-MS approach for the characterization of intact PEGylated proteins. Anal Chem 2014;86:826-34
   PubMed Web of Science ®Google Scholar
• Warrack BM, Redding BP, Chen G, Bolgar MS. Determination of the molecular weight of poly(ethylene glycol) in biological samples by reversed-phase LC-MS with in-source fragmentation. Anal Bioanal Chem 2013;405:4283-7
   PubMed Web of Science ®Google Scholar
• Liu Q, De Felippis MR, Huang L. Method for characterization of PEGylated bioproducts in biological matrixes. Anal Chem 2013;85:9630-7
   PubMed Web of Science ®Google Scholar
• Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010;14:520-8
   PubMed Web of Science ®Google Scholar
• Kontos S, Hubbell JA. Drug development: longer-lived proteins. Chem Soc Rev 2012;41:2686-95
   PubMed Web of Science ®Google Scholar